Vaccination with β2-Microglobulin-Deficient Dendritic Cells Protects Against Growth of β2-Microglobulin-Deficient Tumours |
| |
| Authors: | P. Dammeyer,§ ,A. R. Mwakigonja&dagger ,B. Rethi&Dagger ,F. Chiodi§ ,& E. Z. Wolpert¶ ,§ |
| |
| Affiliation: | Division of Biochemistry, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden;;Department of Oncology-Pathology, Karolinska University Hospital, Stockholm, Sweden;;Institute of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary;;Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden;;and Department of Clinical Science and Education, Södersjukhuset, Karolinska Institute, Stockholm, Sweden |
| |
| Abstract: | Defects in cell surface expression of major histocompatibility complex class I antigen molecules are common in tumour cells. We have previously described the generation of adaptive immunity to tumour cells deficient in the transporter associated with antigen processing molecule. In this study, we demonstrate enhanced in vivo protection against growth of β2-microglobulin-deficient tumour cells in syngeneic C57Bl/6 mice, following vaccination with β2-microglobulin-deficient dendritic cells. In vitro analysis suggested that vaccinated mice produced CD3+ cells, which could induce apoptosis in syngeneic β2-microglobulin-deficient tumour and non-malignant cells. Further investigation of target cell recognition suggested that also tumour cells lacking expression of classical major histocompatibility complex class I heavy chains and functional transporter associated with antigen processing molecules were recognized by CD3+ effector cells from vaccinated mice. Histopathological examination of organs from vaccinated mice showed no significant vaccination-induced pathology. The present findings point to a new possible strategy to counteract the growth of major histocompatibility complex class I-deficient tumour cells. |
| |
| Keywords: | |
|
|
